Exhibit 10.3
[COMPANY LETTERHEAD]
April [__], 2024
[__]
Re: Publicity and Board Observer Rights
Ladies and Gentlemen:
Subject to and in consideration of an investment in Acrivon Therapeutics, Inc., a Delaware corporation (the “Company”), by [__] and/or one or more of its Affiliates (as defined below) (each, an “Investor” and together, the “Investors”), the parties to this letter hereby agree as follows:
2
3
If to the Company:
Acrivon Therapeutics, Inc.
480 Arsenal Way, Suite 100
Watertown, Massachusetts
Attention: Peter Blume-Jensen ; Rasmus Holm-Jorgensen ; Mary-Alice Miller
Email: pblumejensen@acrivon.com; rholmjorgensen@acrivon.com; mmiller@acrivon.com
with a copy (which shall not constitute notice):
Sidley Austin LLP.
787 Seventh Avenue
New York, NY 10019
Attention: Asher Rubin; Istvan Hajdu
Email: arubin@sidley.com; ihajdu@sidley.com
If to the Investors:
[__]
4
Notice will be effective and deemed given only as follows: (a) if given by personal delivery, up-on such personal delivery, (b) if sent for next day delivery by United States Express Mail or overnight delivery service, on the date of delivery as confirmed by written confirmation of delivery, or (c) if sent by electronic mail, upon acknowledgement of receipt other than by automatic means.
[Signature Page Follows]
5
Very truly yours,
|
|
|
COMPANY | ||
|
| |
By: | ||
Name: |
| |
Title: |
|
|
|
|
AGREED AND ACCEPTED: | ||
|
| |
By: | ||
Name: |
| |
Title: |
|